Cost-Effectiveness Modelling of Sequential Biologic Strategies for the Treatment of Moderate to Severe Rheumatoid Arthritis in Finland

OBJECTIVE: The main objective was to compare the cost-effectiveness of therapeutic options in moderate or severe rheumatoid arthritis (RA) when a clinical response to a first TNF-blocker, either etanercept (ETA), adalimumab (ADA), or infliximab (INF), is insufficient. METHODS: Effectiveness criteria...

Descripción completa

Detalles Bibliográficos
Autores principales: Puolakka, K, Blåfield, H, Kauppi, M, Luosujärvi, R, Peltomaa, R, Leikola-Pelho, T, Sennfalt, K, Beresniak, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Open 2012
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349947/
https://www.ncbi.nlm.nih.gov/pubmed/22582103
http://dx.doi.org/10.2174/1874312901206010038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349947/
https://www.ncbi.nlm.nih.gov/pubmed/22582103
http://dx.doi.org/10.2174/1874312901206010038

Ejemplares similares